Burgess B. Freeman

2.5k total citations
43 papers, 747 citations indexed

About

Burgess B. Freeman is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Burgess B. Freeman has authored 43 papers receiving a total of 747 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 16 papers in Oncology and 9 papers in Genetics. Recurrent topics in Burgess B. Freeman's work include Cancer therapeutics and mechanisms (10 papers), Glioma Diagnosis and Treatment (8 papers) and Microtubule and mitosis dynamics (5 papers). Burgess B. Freeman is often cited by papers focused on Cancer therapeutics and mechanisms (10 papers), Glioma Diagnosis and Treatment (8 papers) and Microtubule and mitosis dynamics (5 papers). Burgess B. Freeman collaborates with scholars based in United States, United Kingdom and Canada. Burgess B. Freeman's co-authors include Clinton F. Stewart, Maryam Fouladi, Amar Gajjar, Wayne L. Furman, Najat C. Daw, Peter J. Houghton, Charles H. Fraga, Catherine A. Billups, David C. Turner and Feng Bai and has published in prestigious journals such as Science, Journal of Clinical Oncology and Blood.

In The Last Decade

Burgess B. Freeman

43 papers receiving 737 citations

Peers

Countries citing papers authored by Burgess B. Freeman

Since Specialization

Citations

This map shows the geographic impact of Burgess B. Freeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Burgess B. Freeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Burgess B. Freeman more than expected).

Fields of papers citing papers by Burgess B. Freeman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Burgess B. Freeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Burgess B. Freeman. The network helps show where Burgess B. Freeman may publish in the future.

Co-authorship network of co-authors of Burgess B. Freeman

This figure shows the co-authorship network connecting the top 25 collaborators of Burgess B. Freeman. A scholar is included among the top collaborators of Burgess B. Freeman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Burgess B. Freeman. Burgess B. Freeman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy of oseltamivir treatment in influenza virus-infected obese mice 2023 ·mBio ·Rebekah Honce, Jeremy C. Jones, Victoria Meliopoulos, Brandi Livingston, Bridgett Sharp, Leonardo D. Estrada, Yingzhe Wang, (unknown), Burgess B. Freeman, Elena A. Govorkova, Stacey Schultz‐Cherry	3
2	Abstract 6716: Preclinical evaluation of nano-liposomal irinotecan in pediatric solid tumor patient-derived xenografts 2023 ·Cancer Research ·Elizabeth Stewart, Kaley Blankenship, Burgess B. Freeman, Sara M. Federico, Michael A. Dyer	2
3	Selecting an anti-malarial clinical candidate from two potent dihydroisoquinolones 2021 ·Malaria Journal ·Yizhe Chen, Fangyi Zhu, Jared T. Hammill, Gloria Holbrook, Lei Yang, Burgess B. Freeman, Karen L. White, David M. Shackleford, Kathleen O’Loughlin, Susan A. Charman, Jon C. Mirsalis, R. Kiplin Guy	10
4	Practical approaches to evaluating and optimizing brain exposure in early drug discovery 2019 ·European Journal of Medicinal Chemistry ·Burgess B. Freeman, Lei Yang, Zoran Ranković	15
5	Establishing a Preclinical Multidisciplinary Board for Brain Tumors 2018 ·Clinical Cancer Research ·Birgit Nimmervoll, Nidal Boulos, (unknown), Jason Dapper, Michael DeCuypere, Anang A. Shelat, (unknown), (unknown), Amar Gajjar, Yogesh T. Patel, Burgess B. Freeman, Arzu Onar‐Thomas, Clinton F. Stewart, Martine F. Roussel, (unknown), Thomas E. Merchant, Christopher Calabrese, Karen Wright, Richard J. Gilbertson	9
6	Restoring auditory cortex plasticity in adult mice by restricting thalamic adenosine signaling 2017 ·Science ·Jay A. Blundon, (unknown), Brett J.W. Teubner, (unknown), (unknown), (unknown), Amar K. Pani, Richard J. Smeyne, Seung Baek Han, (unknown), Derek Rose, Troy A. Hackett, (unknown), Burgess B. Freeman, Stanislav S. Zakharenko	32
7	Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study 2016 ·Drug Metabolism and Disposition ·(unknown), Megan O. Jacus, April Davis, Nidal Boulos, David C. Turner, (unknown), Burgess B. Freeman, Richard J. Gilbertson, (unknown)	3
8	Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study 2015 ·Cancer Chemotherapy and Pharmacology ·Yogesh T. Patel, Megan O. Jacus, Nidal Boulos, Jason Dapper, Abigail Davis, (unknown), Burgess B. Freeman, Kumarasamypet M. Mohankumar, Stacy L. Throm, Richard J. Gilbertson, Clinton F. Stewart	6
9	Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing 2014 ·Clinical Cancer Research ·David C. Turner, Fariba Navid, Najat C. Daw, Shenghua Mao, Jianrong Wu, Victor M. Santana, Michael D. Neel, Bhaskar Rao, Jennifer Willert, David M. Loeb, (unknown), Stacy L. Throm, Burgess B. Freeman, (unknown)	40
10	Pemetrexed and Gemcitabine as Combination Therapy for the Treatment of Group3 Medulloblastoma 2014 ·Cancer Cell ·Marie Morfouace, Anang A. Shelat, Megan O. Jacus, Burgess B. Freeman, David C. Turner, (unknown), Frédérique Zindy, Yong‐Dong Wang, David Finkelstein, Olivier Ayrault, Laure Bihannic, Stéphanie Puget, Xiao‐Nan Li, James M. Olson, Giles Robinson, R. Kiplin Guy, (unknown), Amar Gajjar, Martine F. Roussel	99
11	Pharmacokinetics and Efficacy of the Spleen Tyrosine Kinase Inhibitor R406 after Ocular Delivery for Retinoblastoma 2014 ·Pharmaceutical Research ·(unknown), Elizabeth Stewart, Fangyi Zhu, Cori Bradley, Lyra Griffiths, Lei Yang, (unknown), Jiakun Zhang, Burgess B. Freeman, R. Kiplin Guy, Michael A. Dyer	17
12	Deriving therapies for children with primary CNS tumors using pharmacokinetic modeling and simulation of cerebral microdialysis data 2013 ·European Journal of Pharmaceutical Sciences ·Megan O. Jacus, Stacy L. Throm, David C. Turner, Yogesh T. Patel, Burgess B. Freeman, Marie Morfouace, Nidal Boulos, (unknown)	16
13	A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors 2008 ·Investigational New Drugs ·Sunil Sharma, Burgess B. Freeman, (unknown), James T. Symanowski, (unknown), William J. Berg, Nicholas J. Vogelzang	7
14	Population Pharmacokinetic Analysis of Topotecan in Pediatric Cancer Patients 2007 ·Clinical Cancer Research ·Paula Schaiquevich, John C. Panetta, Lisa Iacono, Burgess B. Freeman, Victor M. Santana, Amar Gajjar, Clinton F. Stewart	16
15	Phase I Clinical Trial of Oxaliplatin in Children and Adolescents With Refractory Solid Tumors 2007 ·Journal of Clinical Oncology ·Sheri L. Spunt, Burgess B. Freeman, (unknown), (unknown), Raja B. Khan, Charles B. Pratt, Clinton F. Stewart	23
16	Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma1 2006 ·Neuro-Oncology ·Burgess B. Freeman, Lisa Iacono, John C. Panetta, Amar Gajjar, Clinton F. Stewart	9
17	Evaluation of Gefitinib for Treatment of Refractory Solid Tumors and Central Nervous System Malignancies in Pediatric Patients 2006 ·Cancer Investigation ·Burgess B. Freeman, Najat C. Daw, J. Russell Geyer, Wayne L. Furman, Clinton F. Stewart	30
18	Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors 2006 ·Cancer ·Maryam Fouladi, Susan M. Blaney, Tina Young Poussaint, Burgess B. Freeman, Roger E. McLendon, Christine Fuller, Adekunle M. Adesina, Michael L. Hancock, Mary K. Danks, Clinton F. Stewart, James M. Boyett, Amar Gajjar	38
19	Pharmacokinetics and pharmacodynamics of intravenous epoetin alfa in children with cancer 2005 ·Pediatric Blood & Cancer ·Burgess B. Freeman, Pamela S. Hinds, Lisa Iacono, Bassem I. Razzouk, Elizabeth Burghen, Clinton F. Stewart	7
20	Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC 2005 ·Cancer Chemotherapy and Pharmacology ·Mark N. Kirstein, John C. Panetta, Amar Gajjar, (unknown), Lisa Iacono, Burgess B. Freeman, Clinton F. Stewart	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact